Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Gwénaël Le TeuffAlicia Castaneda-HerediaChristelle DufourTimothy JaspanRaphael CalmonAnnick DevosKieran McHughPierre LeblondDidier FrappazIsabelle AertsChristian Michel ZwaanStéphane DucassouPascal ChastagnerArnauld VerschuurNadège CorradiniMichela CasanovaHervé RubieRiccardo RiccardiMarie-Cecile Le DeleyGilles VassalDidier Frappaznull nullPublished in: Pediatric blood & cancer (2019)
Temozolomide-topotecan results in significant ORR in children with recurrent and refractory medulloblastoma with a favorable toxicity profile.